NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will be a key presenter at the ALS Drug Development Summit in Boston, Mass. on May 22, 2024 , which gathers the top drug developers in the field to present findings and collaborate toward a cure for the disease. Dr. Zimri will present during a session titled, "Exploring the Potentials of Combination Therapy in ALS & Showcasing Latest Progress of PrimeC," in which she will provide an update on the Company's latest findings from its phase 2b clinical trial (PARADIGM). Dr. Zimri will also be leading and moderating a workshop at the pre-conference event, which will delve into the promising field of combination therapy as a novel approach for the treatment of ALS. "I am thrilled to participate in and speak at this conference. I eagerly anticipate sharing our findings and plans, engaging with participants, and exploring new opportunities. The positive reception from the scientific community regardi
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsPR Newswire
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal [Yahoo! Finance]Yahoo! Finance
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealPR Newswire
- NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitPR Newswire
NRSN
Sec Filings
- 6/27/24 - Form 424B3
- 6/27/24 - Form 424B3
- 6/27/24 - Form 6-K
- NRSN's page on the SEC website